Quest PharmaTech Inc.  

(Public, CVE:QPT)   Watch this stock  
Find more results for CVE:qpt
0.030
0.000 (0.00%)
May 22 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.03 - 0.09
Open     -
Vol / Avg. 0.00/6,438.00
Mkt cap 2.51M
P/E     -
Div/yield     -
EPS -0.02
Shares 83.70M
Beta 0.09
Inst. own     -

Key stats and ratios

Q4 (Oct '12) 2012
Net profit margin - -1597.45%
Operating margin - -1597.44%
EBITD margin - -1300.75%
Return on average assets -502.72% -407.09%
Return on average equity - -
Carbon Disclosure Rating - -

Address

8123 Roper Road NW
EDMONTON, AB T6E 6S4
Canada
+1-780-4481400 (Phone)
+1-780-4160324 (Fax)

Website links

External links

Discussion Group - Google Finance

Description

Quest PharmaTech Inc. (Quest) is a biotechnology company. The Company is engaged in the discovery, development and commercialization of pharmaceutical products. It is developing a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, photodynamic therapy, radioimmunotherapy or immunoadjuvants. Quest is also developing a series of products for the treatment of cancer and dermatological conditions, based on its SonoLight Technology platform. Quest is developing monoclonal antibodies targeting certain tumor associated antigens that are presented in various cancers, including ovary, pancreas, lung, breast, prostate and stomach, and monoclonal antibody Oregovomab for the treatment of ovarian cancer. The Company�s product, SL017, is a topical formulation indicated for dermatology applications.

Officers and directors

Lorne Meikle Independent Chairman of the Board
Ragupathy Madiyalakan Ph.D. Chief Executive Officer, Director
Pierre Vermette Chief Financial Officer
Portrait.
Thomas Woo Vice President - Product Development
Ian McConnan Independent Director
Paul J. Van Damme Independent Director